Despite the frequency with which it occurs, familial hypercholesterolemia often goes undiagnosed, with only 10% of affected patients aware of this genetic disorder.
Investigators sought to determine whether angiopoietin-like protein 3 inhibition might improve clinical outcomes in patients with hypertriglyceridemia.
Among those receiving alirocumab + statin therapy to reduce the risk for another CE after a recent ACS, absolute risk reduction is greater for those with diabetes.
Elevated lipoprotein(a) and corresponding LPA genotypes are also associated with an increased risk for ischemic stroke, although the incremental risk is less pronounced.
Adding proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) to background niacin therapy is shown to reduce lipoprotein(a) [Lp(a)] by approximately 15%, according to study results published in the Journal of Clinical Lipidology. In this study, 150 patients were divided into 2 groups: 136 received PCSK9i monotherapy and 14 received PCSK9i and niacin combination therapy. PCSK9i…
Investigators evaluated whether lower on-study and greater percentage reductions in lipoprotein(a) are associated with a lower risk for major adverse cardiovascular events.
Findings of a recently published systematic review and meta-analysis revealed that turmeric and curcuminoids can significantly alter blood lipid levels in patients with metabolic diseases.
Study showed an association between early-onset Alzheimer disease and higher levels of low-density lipoprotein cholesterol independent of the effects of APOE, as well as demonstrated enrichment of rare coding variants of APOB.
